ライフサイエンスコーパス: Fas antigen

1 t express pan B-cell markers did not express Fas antigen.

2 malignant lymphoid cells is mediated by the Fas antigen.

3 ed normal transmembrane and death domains of Fas antigen.

4 ndent reduction in the surface expression of Fas antigen.

5 Bcl-2dim population expressed high levels of Fas antigen.

6 mediated apoptosis includes mutations in the Fas antigen.

7 analysis, all were found to be positive for Fas antigen.

8 expressing comparable levels of cell surface Fas antigen.

9 that was shown previously to associate with Fas antigen.

10 to regulate apoptotic signaling through the Fas antigen.

11 I MHC molecules, and increases expression of fas antigens.

12 Of the 48 BM specimens which did express Fas antigen, 5 (10%) displayed point mutations.

13 Engagement of Fas antigen, a potent effector of apoptosis, activates c

14 Normal expression of cell surface Fas antigen accompanied by defects in late activation th

15 munohistochemical analysis for expression of Fas antigen and CD31 (platelet-endothelial cell adhesion

16 at penetrate the cornea coexpressed both the Fas antigen and CD31.

17 IAV increased neutrophil expression of Fas antigen and Fas ligand, and it also increased releas

18 ed: one in which the interaction between the Fas antigen and its ligand results in apoptosis, and ano

19 Expression levels of cytokines, Fas antigen, and Fas ligand (TaqMan quantitation) in PBM

20 uding orosomucoid, amyloid, metallothionein, Fas antigen, and growth-related genes, including early g

21 g a monoclonal antibody directed against the Fas antigen, apoptosis was induced in freshly isolated m

22 three molecules regulating apoptosis, i.e., Fas antigen, Bax, and p53, at the genomic level in skin

23 to chemosensitivity and re-expression of the Fas antigen, but these cell lines did not regain the abi

24 oma cells (stably transfected to express the Fas antigen CD95, and denoted MCF7F) that lack detectabl

25 iffusely express Fas ligand (CD95L), but not Fas antigen (CD95).

26 poptosis of CD4+ T cells and augmentation of Fas antigen (CD95, APO-1) expression in CD4+ and CD8+ T

27 The Fas antigen (CD95, APO-1) is a transmembrane cell surfac

28 Fas antigen-deficient (lpr) mice or C57BL/6 wild-type mi

29 ly, we demonstrate that mast cells from both Fas antigen-deficient mice and Nf1 +/- mice are resistan

30 background mutant mice which lack functional Fas antigen did not develop apoptosis in their Peyer's p

31 Oncogenic p21(ras) decreases surface Fas antigen expression and renders fibroblasts resistant

32 f1-deficient mast cells have reduced surface Fas antigen expression in response to kit-L and are resi

33 Genetic loss of surface Fas antigen expression leads to reduced apoptosis of mye

34 o decrease p21(ras) activity and up-regulate Fas antigen expression may limit the pathological accumu

35 reaction assays showed that the reduction of Fas antigen expression occurred at the level of transcri

36 ism of drug resistance showed no decrease of Fas antigen expression; however, the apoptotic response

37 g cause of gastric cancer, activation of the Fas antigen (Fas Ag) apoptotic pathway is responsible fo

38 s (PBMCs), but not H. pylori itself, induced Fas antigen (Fas Ag) expression, indicating a Fas-regula

39 cobacter infection up-regulated gastric cell Fas antigen (Fas Ag) mRNA and increased surface receptor

40 as used to identify intrarenal expression of Fas antigen, Fas ligand, granzyme B and perforin in eigh

41 To study the molecular fate of the Fas antigen following receptor activation, a monoclonal

42 Loss of function mutations in the Fas antigen have been associated with congenital autoimm

43 Mutations in the Fas antigen have not been previously described in cancer

44 ncing, we examined the cDNA structure of the Fas antigen in 54 bone marrow (BM) specimens obtained fr

45 The mechanism of Fas antigen-induced hepatocyte apoptosis was investigate

46 ation normal T cell expressed and secreted), Fas antigen, Jun-B, c-Fos, macrophage colony-stimulating

47 ere located in the cytoplasmic region of the Fas antigen known to be involved in transduction of an a

48 Early in infection, Fas antigen-mediated apoptosis depletes parietal and chi

49 hat increased B-cell Ao appears to be a FasL-Fas antigen-mediated process, but is not due to endotoxi

50 ment, there was significant up-regulation of Fas antigen mRNA and membrane localization of the recept

51 s (11%) did not express detectable levels of Fas antigen mRNA.

52 ns remains to be determined, we propose that Fas antigen mutations may contribute to the pathogenesis

53 ession and the functional status of the CD95/Fas antigen on primitive hematopoietic progenitors (PHPs

54 Fas mRNA was increased by 6 hours, whereas Fas antigen on the cell surface increased by 24 hours, w

55 ctivated or transformed cells expressing the Fas antigen on their surface are susceptible to killing

56 from patients with multiple myeloma, express Fas antigen on their surface, but do not undergo apoptos

57 carcinoma cell lines heterogeneously express Fas antigen on their surface.

58 atients display structural defects of either Fas antigen or ligand molecules, and although spontaneou

59 not observed with the p75 TNF receptor, the Fas antigen, or the p75 neurotrophin receptor, which are

60 -7 (Mch-3alpha) were rapidly processed after Fas antigen stimulation.

61 (TNF) receptor shares with the related APO-1/Fas antigen the ability to initiate apoptosis.

62 induced TNF-alpha IFN-gamma secretion and of Fas antigen upregulation.

63 s study, we show that mutations occur in the Fas antigen which may cause loss of function and contrib

64 cell lysates to identify different forms of Fas antigens without immunoprecipitation.